Dopamine D2 receptor occupancy by risperidone:: Implications for the timing and magnitude of clinical response

被引:17
作者
Catafau, Ana M.
Corripio, Iluminada
Perez, Victor
Carlos Martin, Juan
Schotte, Alain
Carrio, Ignasi
Alvarez, Enric
机构
[1] Univ Autonoma Barcelona, Sta Creu & St Pau Hosp, Dept Psychiat, Barcelona 08025, Spain
[2] Univ Autonoma Barcelona, Sta Creu & St Pau Hosp, Dept Nucl Med, Barcelona 08025, Spain
[3] GSK, Ctr Imaging Psychiat, Ctr Excellence Drug Discovery, Barcelona, Spain
[4] Parc Tauli Hosp, Dept Nucl Med, Barcelona, Spain
[5] Janssen Res Fdn, B-2340 Beerse, Belgium
关键词
antipsychotics; dopamine receptors; latency period; schizophrenia; SPECT;
D O I
10.1016/j.pscychresns.2006.02.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The objective of the study is to investigate whether dopamine D2 receptor occupancy by risperidone and plasma levels over time can account for therapeutic efficacy and the latency period to response. Thirty-eight examinations with I-123-IBZM single photon emission computed tomography were performed on 22 patients with schizophrenia, at diagnosis, 48 It after starting risperidone treatment and at a stable dose. Risperidone plasma levels were determined and psychopathologic evaluations (Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale) were carried out. No differences in the striatal/occipital (S/O) ratio or plasma levels were found between examinations at the 48-h time point and when a stable dose level had been established, so these parameters could not account for the latency period required for clinical response. D2 receptor occupancy at 48 h correlated positively with clinical improvement after 2 weeks of treatment. Therefore, if these results are confirmed, D2 receptor occupancy at the beginning of treatment with risperidone may be a predictor of subsequent clinical response. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:175 / 183
页数:9
相关论文
共 36 条
[1]
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia [J].
Abi-Dargham, A ;
Rodenhiser, J ;
Printz, D ;
Zea-Ponce, Y ;
Gil, R ;
Kegeles, LS ;
Weiss, R ;
Cooper, TB ;
Mann, JJ ;
Van Heertum, RL ;
Gorman, JM ;
Laruelle, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) :8104-8109
[2]
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients:: a baseline-endpoint [123I]IBZM SPECT study [J].
Bernardo, M ;
Parellada, E ;
Lomeña, F ;
Catafau, AM ;
Font, M ;
Gómez, JC ;
López-Carrero, C ;
Gutiérrez, F ;
Pavía, J ;
Salamero, M .
PSYCHIATRY RESEARCH-NEUROIMAGING, 2001, 107 (02) :87-97
[3]
STRIATAL DOPAMINE D2-RECEPTOR BLOCKADE BY TYPICAL AND ATYPICAL NEUROLEPTICS [J].
BRUCKE, T ;
ROTH, J ;
PODREKA, I ;
STROBL, R ;
WENGER, S ;
ASENBAUM, S .
LANCET, 1992, 339 (8791) :497-497
[4]
The pharmacology and toxicology of atypical antipsychotic agents [J].
Burns, MJ .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 2001, 39 (01) :1-14
[5]
Catafau AM, 2001, J NUCL MED, V42, P259
[6]
Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone [J].
de Haan, L ;
Lavalaye, J ;
Linszen, D ;
Dingemans, PMAJ ;
Booij, J .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (06) :1019-1020
[7]
Dresel S, 1998, J NUCL MED, V39, P1138
[8]
D1-DOPAMINE AND D2-DOPAMINE RECEPTOR OCCUPANCY DURING TREATMENT WITH CONVENTIONAL AND ATYPICAL NEUROLEPTICS [J].
FARDE, L ;
WIESEL, FA ;
NORDSTROM, AL ;
SEDVALL, G .
PSYCHOPHARMACOLOGY, 1989, 99 :S28-S31
[9]
FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538
[10]
D-2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: A pilot study with sertindole in healthy subjects [J].
Farde, L ;
Mack, RJ ;
Nyberg, S ;
Halldin, C .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 :S3-S7